Full launch of bowel cancer testing service (BC95)
EDX Medical Group PLC
21 July 2026
21 July 2026
("EDX Medical" or the "Group" or "Company")
HIGHLY ACCURATE BOWEL CANCER BIOMARKER TESTING
SERVICE (BC95) NOW AVAILABLE IN UK
CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services for major diseases, announces today the full availability of the Company's comprehensive bowel cancer biomarker testing service in the UK.
The BC95 testing service involves three component tests:
· a highly sensitive biomarker test for the very early detection of bowel cancer
· a comprehensive report on a panel of hereditary genetic risks
· a reference test for faecal haemoglobin which aligns with current NHS practice.
The BC95 service enable sensitivities in excess of 95% across stages 1 to 4 of bowel or colorectal cancer, the second most common cause of cancer related deaths worldwide. More than 46,000 people are diagnosed with bowel cancer every year in the UK, according to Bowel Cancer UK and around 17,700 people die per annum.
EDX Medical initially offered the service to a limited group of clinicians prior to full commercial availability and preliminary clinical evaluation of the BC95 service has indicated particular demand for the early detection test.
EDX Medical has an exclusive agreement with Genomictree Ltd of South Korea, to provide their innovative EarlyTect® epigenetic test that measures aberrant methylation of the SDC2 (Syndecan 2 gene) promoter region, a biomarker that is frequently observed in early-stage colorectal cancer tissues. It is the most sensitive and accurate epigenetic biomarker test for colorectal cancer currently available on the UK market.
In a clinical study of 1124 asymptomatic patients with an overall disease incidence of 1.8%, this test has been shown to have an average sensitivity of 95% for detecting stage 1-4 colorectal cancer, with an exceptionally high sensitivity (89.1%2 ) for detecting very early-stage cancers (stage 0-2). The test even detects pre-cancerous advanced adenomatous polyps with a sensitivity of 58.1%1 making it a particularly useful tool for monitoring those known to have an increased risk of cancer due to hereditary genetics or lifestyle.
Professor Sir Chris Evans, founder of EDX Medical, commented: "We are delighted that early indications from healthcare professionals are showing such strong interest in the early detection element of the testing service and we believe that the combinations of complementary tests available in the BC95 service are unique in the UK. The UK cancer diagnostics market is growing rapidly with a substantial uplift in overall value forecast over the next few years and we believe the BC95 service fits perfectly with the increasing demand for comprehensive and sophisticated diagnostics."
Dr Mike Hudson, chief executive, EDX Medical, commented: "For far too long, late detection of bowel cancer has seriously limited treatment options for patients, and reduced the likelihood of survival, especially at a time when the disease is increasingly occurring in a younger generation of patients. The UK is a key growth market for cancer diagnostics and consumables are the fastest growing segment of the market. The BC95 bowel cancer testing service is an important contribution to detecting bowel cancer early."
Charlotte Rutherford is an advocate who successfully battled Stage 4 bowel cancer after being diagnosed aged 26. She is now in remission and works to raise awareness of the disease.
Charlotte commented: "One of the biggest challenges with bowel cancer is that many people either do not recognise the symptoms or delay seeking advice because they do not think anything is seriously wrong. I am passionate about encouraging people to take control of their own health and not ignore symptoms or warning signs.
"Early diagnosis and early detection are absolutely critical because they can dramatically improve treatment options and outcomes. Innovative testing services such as BC95 give people access to highly accurate screening and detection tools, empowering individuals to be proactive about their health and helping identify bowel cancer at a stage when it is most treatable."
For enquiries, please contact:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609 |
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.